去势抵抗性前列腺癌的新型药物与临床试验：2023年美国临床肿瘤学会-泌尿生殖系统癌症研讨会的最新进展
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
作者信息
Jiang Yuanhong, Wu Siyu, Li Rong, Yu Jiazheng, Zheng Jianyi, Li Zeyu, Li Mingyang, Xin Kerong, Xu Zhenqun, Li Shijie, Chen Xiaonan
机构信息
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
出版信息
Exp Hematol Oncol. 2023 Aug 1;12(1):68. doi: 10.1186/s40164-023-00430-1.
Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.
在2023年美国临床肿瘤学会-泌尿生殖系统（ASCO-GU）癌症研讨会上报告了许多针对去势抵抗性前列腺癌（CRPC）的新型有效治疗药物和临床试验。值得注意的是，放射性核素药物偶联物（RDC），特别是177Lu/111In-J591和225Ac-J591，在治疗CRPC患者方面显示出增强的治疗效果。此外，CRPC的有前景的治疗方法包括在罕见肿瘤中双重抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和抗程序性死亡1（PD-1）阻断（DART）-洛利昔单抗、前列腺干细胞抗原（PSCA）导向的嵌合抗原受体（CAR）-T细胞免疫疗法-BPX-601以及蛋白激酶抑制剂（AKTi）-卡铂特洛-280。我们总结了在2023年ASCO-GU癌症研讨会上提出的最新CRPC治疗策略以及CRPC临床试验的最新进展。
Zotero 插件